Alogliptin in the treatment of type 2 diabetes mellitus: an evidence base for the clinical use


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Type 2 diabetes is a serious disease associated with the development of severe complications. The current treatment, including the use of drugs based on the “incretin effects", and the mechanism of action of dipeptidyl peptidase-4 inhibitors are discussed. The results of clinical studies of the efficacy and safety of alogliptin are presented.

Full Text

Restricted Access

About the authors

E. V Biryukova

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

Email: lena@obsudim.ru
MD, Professor, Department of Endocrinology and Diabetology

References

  1. Papatheodorou K., Papanas N., Banach M., et ai. Complications of Diabetes. J. Diab. Res. 2016;2016:6989453.
  2. Vilsboll T., Holst J.J. incretins, insulin secretion and type 2 diabetes mellitus. Diabetol. 2004; 47:357-66.
  3. Pratley R.E., Salsali A. inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr. Med. Res. Opin. 2007;23:919-31.
  4. Aroda V.R., Henry R.R., Han J., et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review. Clin. Ther. 2012;34(6):1247-58.
  5. Deacon C.F. Dipeptidylpeptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diab. Obes. Metab. 2011;13: 7-18.
  6. Deacon C.F, Lebovitz H.E. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diab. Obes. Metab. 2016;18:333-47.
  7. Johns E., McKay G., Fisher M. Dipeptidyl peptidase-4 (DPP-4) inhibitors. Br. J. Cardiol. 2017;24:(1). doi: 10.5837/bjc.2017.001.
  8. Lim S.W, Jin J. Z., Jin L., et al. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation. Kor. J. intern. Med. 2015;30(6):759-70.
  9. Godinho R., Mega C., Teixeira-de-Lemos E., et al. The Place of Dipeptidyl Peptidase-4 inhibitors in Type 2 Diabetes Therapeutics: A «Me Too» or «the Special One» Antidiabetic Class? J. Diab. Res. 2015;2015:1-28. doi: 10.1155/2015/806979.
  10. Gooßen K, G.räber S. Longer term safety of dipeptidyl peptidase-4 in- hibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis. Diab. Obes. Metab. 2012;14:1061-72.
  11. Алгоритмы специализированной медицинской помощи больных сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, 8-й выпуск. М., 2017. [Algorithms of specialized medical care for patients with diabetes mellitus: clinical guidelines. Ed. by i.i. Dedov, M.V. Shestakova. Moscow, 2017. (in Russ.)].
  12. Baetta R., Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors. Drugs 2011;71(11):1441-67.
  13. Saisho Y. Alogliptin benzoate for management of type 2 diabetes. Vasc. Health Risk Management. 2015:11:229-43.
  14. Dineen L., Law C., Scher R. Alogliptin (Nesina) for Adults With Type-2 Diabetes. PT. 2014;39(3):186, 192-8, 202.
  15. Seino Y., Fujita T., Hiroi S., et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study Curr. Med. Res. Opin. 2011;27:1781-92.
  16. DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, doubleblind, place-bo-controlled study. Diab. Care. 2008;31:2315-17.
  17. Capuano A Sportiello L., Maiorino M.I., Rossi F, et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989-1001.
  18. Seino Y., Yabe D. Alogliptin benzoate for the treatment of type 2 diabetes. Exp. Opin. Pharmacother. 2014;15(6):851-63.
  19. Liu Y., Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diab. Obes. Metab. 2014;16(2):111-17. doi: 10.1111/ dom.12128. [Epub 2013 Jun 3].
  20. Chon S., Gautier J-F An Update on the effect of incretin-based therapies on ß-cell function and mass. Diab. Metab. J. 2016;40:99-114.
  21. Wu D., Li L., Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a metaanalysis Diab. Obes. Metab. 2014;16(1):30-7. doi: 10.1111/dom.12174. Epub 2013 Jul 16.
  22. DeFronzo R.A., Hissa M.N., Garber A.J., et al.; Saxagliptin 014 Study Group. The Efficacy and safety of alogliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diab. Care. 2009;32(9):1649-55.
  23. Stahn A., Pistrosch F., Ganz X., et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diab. Care. 2014;37: 516-20.
  24. Del Prato S., et al. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diab. Obes. Metab. 2014;16(12):1239-46.
  25. Khaled A.A., Sekaran M., Ikram S.I. Type 2 diabetes and vascular complications: A pathophysiologic view. Biomed. Res. 2010;21(2):147-55.
  26. Leon B.M., Maddox T.M. Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diab. 2015;6(13):1246-58.
  27. Zoungas S., Patel A. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies. Ann. N. Y Acad. Sci. 2010;1212(1):29-40.
  28. Low Wang C.C., Hess C.N., Goldfine A.B. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459-502. Doi:10.1161/ CiRCULATiONAHA.116.022194.
  29. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013;369:1327-35.
  30. Khan M., Deaton C., Rutter M., etal. Incretinsasanovel therapeutic strategy in patients with diabetes and heart failure. Heart Fail. Rev. 2013;18:141-48.
  31. Chrysant S.G., Chrysant G.S. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. Am. J. Cardiol. 2012;109(11):1681-85.
  32. Lund A. On the role of the gut in diabetic hyperglucagonaemia. Dan. Med. J. 2017;64(4):pii:B5340.
  33. Pratley R.E., McCall T., Fleck PR., et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J. Am. Geriatr. Soc. 2009;57(11):2011-19.
  34. Rosenstock J., Wilson C., Fleck P Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diab. Obes. Metab. 2013;15(10):906-14. doi: 10.1111/dom.12102.
  35. Bron M., Wilson C., Fleck P A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diab. Ther. 2014;5:521-34.
  36. Moritoh Y., Takeuchi K., Asakawa T, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008;588(2-3):325-32.
  37. Kawashima S., Matsuoka T.A., Kaneto H., et al. Effect of alogliptin, pioglitazone and glargine on pancreatic beta-cells in diabetic db/db mice. Biochem Biophys Res Commun. 2011;404(1):534-40.
  38. Zhang X., Wang Z., Huang Y., Wang J. Effects of chronic administration of alogliptin on the development of diabetes and beta-cell function in high fat diet/streptozotocin diabetic mice. Diabetes Obes Metab. 2011;13(4):337-47.
  39. Yin H., Park S.Y., Wang X.J., et al. Enhancing pancreatic beta-cell regeneration in vivo with pioglitazone and alogliptin. PLoS One. 2013;8(6):e65777.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies